Oncology Hematology Care, Cincinnati
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus

Набиране на участнициФаза 2

Възраст 18 и повече · Всички полове · Обновено на 14.09.2026 г. · NCT06297226

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

TriHealth Cancer and Blood Institute, Cincinnati

Набиране на участнициФаза 3

Възраст 18 и повече · Всички полове · Обновено на 11.09.2026 г. · NCT07555938

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Research Site, Cleveland

Набиране на участнициФаза 1/2

Възраст 18 и повече · Всички полове · Обновено на 27.08.2026 г. · NCT07681596

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Oncology Hematology Care Clinical Trials, LLC, Cincinnati
TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
Oncology Hematology Care Clinical Trials, LLC, Cincinnati
и още 5

Набиране на участнициФаза 3

Възраст 18 и повече · Всички полове · Обновено на 24.08.2026 г. · NCT06152575

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Gabrail Cancer & Research Center, Canton

Набиране на участнициФаза 1/2

Възраст 18 и повече · Всички полове · Обновено на 24.08.2026 г. · NCT06087653

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

GSK Investigational Site, Canton

Набиране на участнициФаза 1/2

Възраст 18 и повече · Всички полове · Обновено на 19.08.2026 г. · NCT05714839

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

OhioHealth O'Bleness Hospital, Athens
Good Samaritan Hospital - Cincinnati, Cincinnati
Bethesda North Hospital, Cincinnati
и още 15

Набиране на участнициФаза 3

Възраст 18 и повече · Всички полове · Обновено на 19.08.2026 г. · NCT04566328

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Ohio State University, Columbus

Набиране на участнициФаза 1/2

Възраст 18 и повече · Всички полове · Обновено на 18.08.2026 г. · NCT06292780

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Cleveland Clinic - Taussig Cancer Institute, Cleveland

Набиране на участнициФаза 1

Възраст 18 и повече · Всички полове · Обновено на 18.08.2026 г. · NCT05651932

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Research Site, Cincinnati
Research Site, Cleveland
Research Site, Columbus
и още 1

Набиране на участнициФаза 3

Възраст 18 и повече · Всички полове · Обновено на 14.08.2026 г. · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Ohio State University Comprehensive Cancer Center, Columbus

Набиране на участнициФаза 1

Възраст 18 и повече · Всички полове · Обновено на 12.08.2026 г. · NCT07280013

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
The Ohio State University /ID# 271336, Columbus

Набиране на участнициФаза 1/2

Възраст 18 и повече · Всички полове · Обновено на 21.07.2026 г. · NCT06892522

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

University Of Cincinnati Medical Center /ID# 251746, Cincinnati

Набиране на участнициФаза 1

Възраст 18 и повече · Всички полове · Обновено на 13.07.2026 г. · NCT05650632

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Ohio State University Comprehensive Cancer Center, Columbus

Набиране на участнициФаза 2

Възраст 18 и повече · Всички полове · Обновено на 8.07.2026 г. · NCT07657312

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

The Ohio State University James Cancer Hospital, Columbus

Набиране на участнициФаза 1

Възраст 18 и повече · Всички полове · Обновено на 8.07.2026 г. · NCT05137054

Integrated Cancer Repository for Cancer Research

Aultman Alliance Community Hospital, Alliance
Aultman Hospital, Canton

Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли

Възраст от 19 до 110 · Всички полове · Обновено на 29.06.2026 г. · NCT02012699

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Indu and Raj Soin Medical Center, Beavercreek
Saint Elizabeth Boardman Hospital, Boardman
Dayton Physicians LLC-Miami Valley South, Centerville
и още 17

Набиране на участнициФаза 3

Всички възрасти · Всички полове · Обновено на 10.06.2026 г. · NCT05561387

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

University of Cincinnati, Cincinnati
Seidman Cancer Center-University Hospitals Cleveland Medical Center, Cleveland
Ohio State Medical Center, James Cancer Center, Columbus
и още 1

Набиране на участнициФаза 3

Възраст 18 и повече · Всички полове · Обновено на 4.06.2026 г. · NCT05243797

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

The Ohio State University- The James Cancer Hospital and Solove Research Institute, Columbus

Набиране на участнициФаза 2

Възраст 19 и повече · Всички полове · Обновено на 4.06.2026 г. · NCT06974786

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

The Ohio State University Comprehensive Cancer Center, Columbus

Набиране на участнициФаза 2

Възраст 18 и повече · Всички полове · Обновено на 2.06.2026 г. · NCT05145400

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center, Columbus

Набиране на участници

Възраст 18 и повече · Всички полове · Обновено на 27.05.2026 г. · NCT07609030

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Cincinnati Children's Hospital Medical Center, Cincinnati
University of Cincinnati, Cincinnati
The Ohio State University, Columbus

Набиране на участнициФаза 1

Възраст 13 и повече · Всички полове · Обновено на 5.05.2026 г. · NCT04771572

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

GSK Investigational Site, Columbus

Набиране на участнициФаза 3

Възраст 18 и повече · Всички полове · Обновено на 22.04.2026 г. · NCT06679101

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Oncology Hematology Care, Cincinnati

Набиране на участнициФаза 2

Възраст 18 и повече · Всички полове · Обновено на 22.04.2026 г. · NCT05972135

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Ohio State University James Cancer Hospital, Columbus

Набиране на участнициФаза 1/2

Възраст 18 и повече · Всички полове · Обновено на 20.04.2026 г. · NCT03761108

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

The Ohio State University Comprehensive Cancer Center, Columbus

Набиране на участнициФаза 1/2

Възраст 12 и повече · Всички полове · Обновено на 24.03.2026 г. · NCT04988555

От ClinicalTrials.gov, данни към 4.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.